6550--ALBAcyte Red Blood Cell Reagents-Notice of Intent to Sole Source
ID: 36C25024Q1090Type: Special Notice
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OF250-NETWORK CONTRACT OFFICE 10 (36C250)DAYTON, OH, 45428, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/ef4f00e13f944067be24f0e761dc42a3/view
Timeline
    Description

    The Department of Veterans Affairs, specifically the Network Contracting Office 10, intends to negotiate a sole source contract for ALBAcyte Red Blood Cell Reagents with Alba Bioscience Inc. This procurement is essential for the Blood Bank Department at the Richard L. Roudebush VA Medical Center, as it involves specialized reagents necessary for blood typing and compatibility testing critical for patient transfusions. The urgency of this acquisition is underscored by the unique quality of the reagents from Alba Bioscience, which eliminates the need for repeated validations from other sources. Responses to this notice must be submitted by 2:00 pm EST on September 23, 2024, to Contract Specialist Lonnelle Jones at lonnelle.jones@va.gov, as no solicitation package will be provided.

    Point(s) of Contact
    Lonnelle JonesContract Specialist
    (371) 988-1545
    lonnelle.jones@va.gov
    Files
    Title
    Posted
    36C25024Q1090.docx
    The Department of Veterans Affairs (VA), Network Contracting Office 10, intends to negotiate a sole source contract for ALBAcyte Red Blood Cell Reagents, specifically with Alba Bioscience Inc. This action, guided by FAR Part 6.302-1, indicates that only one source can fulfill the requirements, justifying the sole source procurement. The contract will be fixed price without option years, covering various items including ALBAcyte A1, A2, and B cells, among others. Responses to this notice must demonstrate compelling evidence that competition is beneficial, though no solicitation package is provided. The deadline for responses is set for September 23, 2024, at 2:00 pm EST. The intent to proceed without open competition underscores the specific capabilities of Alba Bioscience Inc. as essential for meeting the VA's needs effectively. The contact person for this notice is Contract Specialist Lonnelle Jones.
    P03 LSJ-Red Blood Cells_Redacted.pdf
    The Department of Veterans Affairs is seeking to establish a five-year contract with Alba Bioscience Inc. for the supply of red blood cell reagents at the Richard L. Roudebush VA Medical Center. This acquisition is vital for the Blood Bank Department, as it involves specialized testing for blood typing and compatibility assessments essential for patient transfusions. The reagents listed are exclusively from Alba Bioscience due to their unique quality and the requirement for controls that avoid repeated validations from other sources. The contract is justified under the Federal Acquisition Regulation (FAR) allowing limited sourcing when only one vendor can meet the needs effectively. The inquiry showed no other vendors could provide the required reagents. The estimated delivery date is October 1, 2024. This sole-source procurement underscores the urgency and necessity of maintaining patient care standards without causing delays that could impact healthcare delivery. The justification document complies with all applicable regulations, including those surrounding the Federal Supply Schedule program.
    Lifecycle
    Title
    Type
    6550--ALBAcyte Red Blood Cell Reagents-Notice of Intent to Sole Source
    Currently viewing
    Special Notice
    Similar Opportunities
    6550--VISN Multiplex PCR Testing Reagents/Consumables Intent to sole source
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Great Lakes Acquisition Center, intends to negotiate a sole source contract with BioMerieux, Inc. for the provision of proprietary reagents and consumables necessary for PCR testing on government-owned devices across facilities in Wisconsin, Illinois, and Michigan. This procurement is essential to ensure that the VA can maintain high-quality healthcare services, as only BioMerieux is deemed capable of meeting the specialized requirements for these supplies. The contract will be established as a Blanket Purchase Agreement (BPA) under an existing contract, categorized as firm fixed price, and is being conducted in accordance with FAR 8.405-6. Interested firms must submit their qualifications and relevant customer references to the Contracting Officer, Teresa Beers, at teresa.beers@va.gov within seven calendar days from the publication date of this notice, as no competitive proposals will be solicited.
    6640--Benchtop flow cytometer Intent to Sole Source
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 6, intends to award a sole source Firm-Fixed-Price purchase order for an Accuri C6 Plus system from Becton, Dickinson and Company (BD Biosciences). This procurement is aimed at acquiring specialized instruments intended solely for research purposes, not for diagnostic or therapeutic use, highlighting the need for proprietary equipment in the VA's operational framework. Interested parties are invited to demonstrate their capability to meet this requirement by submitting supporting evidence by September 20, 2024, at 4 PM EST, with all inquiries directed to Contracting Officer Jamie Sullivan via email at jamie.sullivan4@va.gov.
    6550--VISN 6 BioFire FilmArray Verification Kits.
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to negotiate a sole source contract for the procurement of BioFire FilmArray Verification Kits from Biomerieux, Inc., to meet the specialized needs of the Veterans Integrated Service Network (VISN) 6. The contract will include various diagnostic panels, with specific quantities required for each type, ensuring that the VA can provide timely and effective medical services to veterans. This procurement is critical as these specialized diagnostic supplies are only available from a single source, emphasizing the importance of maintaining compliance with federal regulations and the efficient delivery of healthcare services. Interested firms may express their capabilities to the Contract Specialist, LaToya Glover, via email by September 23, 2024, with the contract expected to be awarded effective October 1, 2024.
    Kidney Reagents for Luminex 3D Analyzer
    Active
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source contract for Kidney Reagents for the Luminex 3D Analyzer, specifically for the Kidney Transplant Clinic at The Walter Reed National Military Medical Center in Bethesda, Maryland. The procurement aims to secure molecular and serological reagents from One Lambda Inc. that are essential for transplant testing, ensuring compatibility and reducing the risk of organ rejection between donors and recipients. These reagents are critical as they have been validated by the American Society of Histocompatibility and Immunogenetics (ASHI) and are necessary for maintaining the accreditation of the Immunology Lab. Interested parties may express their interest and provide a capability statement to Barbara Sonnier at barbara.n.sonnier.civ@health.mil by September 24, 2024, at 10:00 PM EST.
    6515--Nucleic Acid Purification System - Research, Ann Arbor
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to negotiate a sole source contract for a Nucleic Acid Purification System for the LTC Charles S. Kettles VA Medical Center in Ann Arbor, MI. This procurement will be executed under Simplified Acquisition Procedures, citing FAR Part 6.302-1, as the government believes that only Fisher Scientific possesses the necessary capabilities to fulfill this requirement. The Nucleic Acid Purification System is critical for medical research and diagnostics, ensuring high-quality results in nucleic acid extraction processes. Interested parties should note that the response deadline is September 23, 2024, by 4 PM Eastern Time, and inquiries can be directed to Contracting Officer James Howard at james.howard3@va.gov.
    6640--BD MAX REAGENTS STL
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to provide molecular testing and extraction supplies for the BD MAX instrument at the St. Louis VA Medical Center. This procurement involves a Firm Fixed Price Blanket Purchase Agreement (BPA) for specific reagents necessary for nucleic acid detection and extraction, with an estimated contract duration of one base year and four optional yearly ordering periods, commencing from November 1, 2024, to October 31, 2029. The supplies are critical for ensuring uninterrupted patient care operations, and interested parties, particularly Service-Disabled Veteran Owned Small Businesses, must submit their responses by September 20, 2024, to Contract Specialist Michael P. Murphy at michael.murphy7@va.gov. The government does not guarantee any contract awards based on this notice, which serves solely for market research purposes.
    Chemistry and Immunochemistry
    Active
    Veterans Affairs, Department Of
    Special Notice: VETERANS AFFAIRS, DEPARTMENT OF is seeking Chemistry and Immunochemistry services. This procurement is typically used for analytical laboratory testing and research. The contract will be awarded to ABBOTT LABORATORIES on October 1, 2024, and will be in effect until September 30, 2029. The place of performance is Montgomery, Alabama, United States. The contract is a firm-fixed price sole source requirement. For more information, please contact Derrell D Calhoun at Derrell.Calhoun@va.gov or 4782721210.
    Notice of Intent to Sole Source - Ortho-Clinical Blood Cards Reagent -
    Active
    Dept Of Defense
    The Department of Defense, specifically the Army Health Contracting Activity, intends to award a sole source contract to Ortho-Clinical Inc. for the procurement of red blood cell reagent cards necessary for the Government-owned Ortho Vision ID-MTS Workstation analyzer at Irwin Army Community Hospital in Fort Riley, Kansas. This procurement is classified as sole source due to the unique proprietary nature of the required supplies, which are exclusively produced by Ortho Clinical Diagnostics and have a short expiration period, necessitating timely acquisition. The contract is expected to be awarded on or about September 17, 2024, with funding anticipated from FY 2025, and interested parties may direct inquiries to Perry J. Cannon at perry.j.cannon.civ@health.mil.
    6505--Lymphoseek IDIQ
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 22, intends to award a Sole Source contract for the procurement of Lymphoseek, a proprietary radiopharmaceutical, primarily for use at the VA Loma Linda Healthcare System. This contract, designated as Solicitation Number 36C26225Q0026, will be structured as a Firm Fixed-Price Indefinite Quantity Indefinite Delivery (IDIQ) with a base year and four option years, with an estimated quantity of 86 study doses required annually. Lymphoseek is critical for identifying sentinel lymph nodes in melanoma patients, providing superior image quality due to its targeted action on the CD206 receptor. Interested parties may submit a capabilities statement by September 27, 2024, at 10:00 AM Pacific Time, and should direct inquiries to Hestia Sim at Hestia.Sim@va.gov.
    6640--Electrophoresis Testing VA VISN2
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified small businesses to provide electrophoresis testing services under an Indefinite Delivery contract for its Upstate New York Medical Center Laboratories located in Albany, Buffalo, and Syracuse. The contract will cover various types of electrophoresis testing, including Serum Protein Electrophoresis (SPEP), Urine Protein Electrophoresis (UPEP), Immuno-Fixation Electrophoresis (IFE), and Cerebral Spinal Fluid (CSF)/Oligoclonal Bands, which are critical for diagnosing conditions such as Multiple Myeloma and Multiple Sclerosis. The contract period is set from October 1, 2024, to September 30, 2029, with a submission deadline for quotes by 4:00 PM on September 23, 2024. Interested parties should direct inquiries to Contract Specialist Sam A DeMuzio at sam.demuzio@va.gov or call (585) 393-7735.